AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05937243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advanced Digital Data Sharing (ADDS) with Coaches
Description: When Advanced DDS with Coaches is turned ON, coaches having a bachelor's degree in health-related fields will have access to a secure web portal called the clinical portal. The portal will also mimic four key behavior change techniques typically employed by an expert clinician including 1) gather data on target behaviors from the base self-help app (i.e., uptake of weekly module, self-monitoring compliance, and skills use), 2) synthesize participants' behavioral data on treatment targets, 3) flag data to indicate behaviors needing improvement and 4) use sophisticated algorithms to generate recommendations for intervening on identified data patterns. Using this information, the coaches will send one weekly email to facilitate improvement in treatment targets over 12 weeks. When Advanced DDS with Coaches is turned OFF, participants' will not have their data shared and will not receive emails from the coaches.
Study NCT04539405 — intervention group
Intervention type: DEVICE
Intervention: To evaluate sevoflurane consumption when using Memsorb
Description: Sevoflurane administration at 0.2L.min-1 (minimal gas flow)
Study NCT04539405 — intervention group
Intervention type: DEVICE
Intervention: To evaluate sevoflurane consumption when using classical Dräegersorb
Description: Sevoflurane administration at 2L.min-1 (classical gas flow)
Study NCT06571526 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: External focus
Description: The training phase consisted of 20 consecutive training trials, with a rest interval of at least 30 seconds between trials. All participants had to circumvent an obstacle during each trial on the 8-m level-ground walkway. During each trial, the general instruction was to focus on a random series of digits ranging from 0 to 9 displayed on monitors placed at the immediate and future destinations of the walkway. Each number was displayed for at least 2 seconds to allow participants to have sufficient time to read them.
Study NCT05021263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Medications
Description: IV magnesium sulfate, used to replete magnesium stores
Study NCT05021263 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT05681663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroshock Wave therapy
Description: Randomized- Controlled trial
Study NCT04471142 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neuromuscular bandage
Description: After the dressing is performed by the nursing team with a sterile gauze covering over the region of the healing points, the 7 cm wide Vitaltape® neuromuscular bandage will be applied. For the application of the bandage, maximum stretching will be performed over the region of the plastron and finished with the two ends, from two to three centimeters, without stretching. As many bundles of bandages as necessary will be applied according to the patient's body characteristics.
Study NCT06571526 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The training phase consisted of 20 consecutive training trials, with a rest interval of at least 30 seconds between trials. All participants had to circumvent an obstacle during each trial on the 8-m level-ground walkway. During each trial, the general instruction was to walk to the end of the walkway at your natural pace.
Study NCT06409013 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study NCT06283966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGF MDI 320/14.4/9.6 μg
Description: Budesonide, glycopyrronium, and formoterol fumarate pressurized inhalation suspension
Study NCT06283966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFF MDI 14.4/9.6 μg
Description: Glycopyrronium and formoterol fumarate pressurized inhalation suspension
Study NCT05771012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.05% cyclosporin (Restasis®, Allergan Inc)
Description: study the efficacy of topical 0.05% cyclosporin eye drops (Restasis®, Allergan Inc) in management of grade 1 and 2 acquired punctal stenosis (group A)
Study NCT05771012 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mini-monoka stent
Description: insertion of mini-monoka stent in the lower punctum in management of grade 1 and 2 acqquired punctal stenosis (group B)
Study NCT05788120 — intervention group
Intervention type: OTHER
Intervention: Follow up by phone call
Description: Centralized review of ECGs by the Pitié-Salpêtrière rhythmology department and collection of vital status at 12 months (if information not available, telephone call to the patient)
Study NCT05735197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg Tab
Description: Dapagliflozin which is (SGLT2 inhibitor) will be used as add on medication.
Study NCT05735197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo which has the same shape as Dapagliflozin but without active ingredient will be used as add on medication for control group.
Study NCT04392622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Limonene Gelcaps
Description: Administered orally at 2 to 8 grams daily
Study NCT04392622 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiotherapy (IMRT)
Description: Standard of Care -All patients will receive standard radiation treatment of 66 to 70 Gy given in 33 to 35 fractions (2 to 2.12 Gy/fractions) over 6.5 to 7 weeks.
Study NCT04392622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Standard of Care -Cisplatin as 100 mg/m2 IV
Study NCT04392622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Xerostomia questionnaire
Description: Xerostomia questionnaire consists of 4 items on dryness while eating/speaking and 4 on dryness at rest. Patients rate each symptom on an 11 point ordinal Likert scale from 0 to 10, with higher scores indicating greater xerostomia
Study NCT05817786 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrical stimulation of the brachial plexus nerve roots
Description: treated by chronic electrical stimulation of the brachial plexus nerve roots
Study NCT05817786 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sham stimulation
Description: treated by sham stimulation
Study NCT06186284 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: nerve conduction study
Description: sensory and motor nerve conduction study of both median nerves and ulnar nerves
Study NCT06186284 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ultrasonography wrists
Description: assess the cross-sectional area of the median nerves and the ulnar nerves
Study NCT06186284 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Boston carpal tunnel questionnaire
Description: assess the severity of symptoms and the functional impact related to carpal tunnel syndrome
Study NCT06186284 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: clinical provocative tests for carpal tunnel syndrome
Description: Tinel and Phalen's test to evaluate the presence of carpal tunnel syndrome
Study NCT06415240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facilitated Tucking
Description: Facilitated Tucking is a position to be adopted for pain relief in neonates.
Study NCT06415240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gentle Human Touch
Description: while gentle human touch is caressing on head for pain relief.
Study NCT05334940 — intervention group
Intervention type: OTHER
Intervention: not applicable, observational study
Description: Patients do not receive intervention
Study NCT06014801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dialysate fluid, Filtration replacement fluid
Description: Dose of continuous hemodialysis and/or hemofiltration
Study NCT06014801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dialysate fluid, Filtration replacement fluid
Description: Dose of continuous hemodialysis and/or hemofiltration
Study NCT05430438 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dialysis with low dialysate sodium concentration
Description: Patients will undergo 4 dialysis sessions with a dialysate sodium concentration of 137 mEq/L. The modification of dialysate sodium concentration will be monitored through alteration of sodium conductivity
Study NCT05430438 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dialysis with standard dialysate sodium concentration
Description: Patients will undergo 4 dialysis sessions with a dialysate sodium concentration of 140 mEq/L. The modification of dialysate sodium concentration will be monitored through alteration of sodium conductivity
Study NCT04855890 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation
Description: The ablation procedure will be performed during deep sedation using midazolam, fentanyl and a continuous infusion of propofol. Vital parameters will be monitored. For catheter access three 8F sheaths will be inserted into the femoral veins. A multipolar diagnostic catheter will be placed in the coronary sinus. Single transseptal puncture and insertion of a 8.5 F transseptal sheath or 12F Cryo-Sheath (FlexCath AdvanceTM, Medtronic, Minneapolis, MN, USA) will be followed by PV angiographies. Before or shortly after transseptal puncture unfractionated heparin will be repeatedly administered to maintain an activated clotting time between 250 and 400s.
Study NCT06551727 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: After stroke progression, all patients receive dual antiplatelet therapy (aspirin 100mg/day combined with clopidogrel 75mg/day) for the first 21 days, except in cases of cerebral hemorrhage. After this period, they continue to take aspirin 100mg/day orally for the long term.~In terms of blood pressure control, medications such as dopamine, metaraminol, or midodrine are used to achieve a systolic blood pressure target range of 160-180 mmHg within 1 h of random assignment and to maintain this target for 7 days (or death, should this event occur earlier). BP measurements are routinely captured using automated devices fitted to the unaffected arm, following the protocol recommended by the standard guideline. The readings are taken at 15-minute intervals for the initial hour, hourly from the first to the sixth hour, every six hours from 6 to 24 hours, and then twice daily for 7 days (or death, if earlier). Subsequently, these data are uploaded into the research database.
Study NCT06551727 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: After stroke progression, all patients receive dual antiplatelet therapy (aspirin 100mg/day combined with clopidogrel 75mg/day) for the first 21 days, except in cases of cerebral hemorrhage. After this period, they continue to take aspirin 100mg/day orally for the long term.
Study NCT04715581 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Preoperative nutritional optimization
Description: 1. Indication for oral nutritional supplementation: Patients at risk of malnutrition (MNA-SF 8-11) or with malnutrition (MNA-SF 0-7).~2. Protocol of nutritional optimization: Enteral nutritional powder (Ensure for patients without diabetes and Glucerna for patients with diabetes) twice a day. The target protein intake is 1.5-1.8 g/kg/d. Patients with iron deficient anemia (hemoglobin \<130 g/L for men and \<120 g/L for women) will be given oral iron therapy.~3. The duration of nutritional optimization: The day admitted to the hospital to the surgery to one day prior to the surgery.
Study NCT04715581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preoperative exercise training
Description: 1. The respiratory training will be performed for at least 2-3 times per day. Respiratory training include thoracic breathing exercise and cough training.~2. Aerobic exercise will be performed for at least 1-2 times per day. Aerobic exercise includes jogging, walking or climbing stairs. Exercise intensity will be based on patients' tolerance. The goal of the training is to complete the training plan as far as possible.~3. Every training should be last for 45 minutes to 1 hour. If the patient can not tolerate, the training time should be reduce to 30 minutes.~4. The duration of exercise training: The day admitted to the hospital to the surgery to one day prior to the surgery.
Study NCT04715581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postoperative exercise training
Description: 1. Muscle strength training in the bedside and walking in the ward.~2. Aerobic exercise includes jogging, walking or climbing stairs. Exercise intensity will be based on patients' tolerance. The goal of the training is to complete the training plan as far as possible.~3. Exercise training is performed under the supervision of physiotherpists durign hospital stay, and is reminded by regular telephone calls and phone messages after hospital discharge.
Study NCT05146232 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: monitoring
Description: electrocardiogram, noninvasive blood pressure, SpO2, rSO2 (Masimo oximeter), and neuromuscular monitoring (TOF-Watch SX; Organon, Dublin, Ireland) were performed on the patients.
Study NCT05146232 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: First postoperative analgesia
Description: IV acetaminophen will be administered every 6 h
Study NCT05146232 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Second postoperative analgesia
Description: 50 mg IV dexketoprofen every 8 h for the first 48 h.
Study NCT06338553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsule or tablet once before the pre-TZIELD® MMTT and once before one of the post-TZIELD® MMTTs.
Study NCT06338553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide (Rybelsus®)
Description: 7 mg single dose of Rybelsus® by mouth once before one of the post-TZIELD® MMTTs
Study NCT06540911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized physical back training program
Description: The study intervention is a 4-week personalized physical back training program. The study intervention consists of six exercises selected from a predefined set by a physical therapist or medical doctor. These exercises are selected through a clinical reasoning process, i.e., they are tailored and problem-oriented, based on the results of a clinical assessment.
Study NCT06540911 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-personalized physical back training program
Description: The control intervention is a 4-week non-personalized physical back training program. The control intervention consists of six exercises selected from a predefined set by a physical therapist or medical doctor. These exercises are not selected through a clinical reasoning process, i.e., they are neither tailored nor problem-oriented nor based on the results of a clinical assessment.
Study NCT05851547 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prostate SBRT with Focal Boost
Description: Prostate stereotactic body radiotherapy delivered to 27 Gy in 3 fractions on alternating days to uninvolved regions with up to 39 Gy in 3 fractions delivered to mpMRI-defined intraprostatic lesions
Study NCT05851547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin Injection
Description: Six months of androgen deprivation therapy for intermediate-risk localized prostate cancer and 24 months for high-risk localized prostate cancer
Study NCT05829044 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pupillometry
Description: Pupillometer measurement of pupil size in response to different light stimuli
Study NCT05829044 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light box exposure
Description: Using a light box to produce different wavelengths and intensities of light. Exposure to red light on Night 1 and blue/green light on Night 2 to determine circadian timing and suppression of hormone (melatonin)
Study NCT06284122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: 5 mg (step-up dosing) Day 1 of C1 45 mg Day 8 and Day 15 of C1, 45 mg Day 1 from C2 to C12, 45 mg Day 1 from C13 to C21
Study NCT06284122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 20 mg/day Day 1 to Day 21 from C2 to C12
Study NCT06284122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: when associated to CHOP IV 375mg/m² SC 1400 mg allowed from C2 Day 1 of C1 Day 1 from C2 to C6 Day 1 from C7 to C20
Study NCT06284122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obinutuzumab
Description: when associated to CHOP 1000 mg Day 1, Day 8, Day 15 of C1 Day 1 from C2 to C8 Day 1 from C9 to C18
Study NCT06284122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 750 mg/m2 Day 1 from C1 to C6
Study NCT05115890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Patients with HFpEF will undergo 8 weeks of exercise training.
Study NCT05904912 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Postoperative analgesia management
Description: Intravenous 0.5 mg/kg tramodol and 1 gr paracetamol will be administered to all patients 30 minutes before the end of the surgical procedure. In the postoperative period, patients will be administered iparacetamol iv 1 gr 3x1. Postoperative patient evaluation will be performed by another pain nurse who is unaware of the procedure. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic.
Study NCT05904912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative analgesia management
Description: Intravenous 0.5 mg/kg tramodol and 1 gr paracetamol will be administered to all patients 30 minutes before the end of the surgical procedure. In the postoperative period, patients will be administered iparacetamol iv 1 gr 3x1. Postoperative patient evaluation will be performed by another pain nurse who is unaware of the procedure. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic.
Study NCT05904912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PENG-Bupivacaine
Description: The probe will be placed on the anterior inferior iliac crest in the transverse plane. Then, the pubic ramus will be visualized by rotating 45 degrees. The femoral artery, iliopubic process, and psoas muscle will be visualized. The needle will be punctured with the in-plane method to reach between the pubic ramus and the psoas tendon. After the block area is confirmed with 5 ml of saline, 30 ml of local anesthetic solution containing 0.25% bupivacaine will be injected.
Study NCT05904912 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Local infiltration-Bupivacaine
Description: Local infiltration will be applied with 30 ml of a local anesthetic solution containing 0.25% bupivacaine by the surgical team
Study NCT05409495 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: periodontal surgical procedure (open flap debridement)
Description: All surgical procedures were performed by the second periodontist. 0.12% Chlorhexidine digluconate (CHX) rinse for intraoral antisepsis and a povidone iodine solution was used for extraoral antisepsis. After local anesthesia (2% lidocaine with epinephrine 1:100,000/ Astra, Westbrough, MA) was applied, the full thickness trapezoidal flap was raised large enough to provide adequate view of the defect area. Subgingival debridement and root planning were performed with the use of area-specific curets (Gracey curets, Hu-Friedy), and granulation tissue was removed The IBD area in the control group was closed without applying any material. Then mucoperiosteal flaps were repositioned with sutured with 4/0 monoprolene sutures.
Study NCT05409495 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: periodontal surgical procedure (OFD +autogenous Titanium-prepared platelet-rich fibrin (OFD+ T-PRF))
Description: All surgical procedures were performed by the second periodontist. 0.12% Chlorhexidine digluconate (CHX) rinse for intraoral antisepsis and a povidone iodine solution was used for extraoral antisepsis. After local anesthesia (2% lidocaine with epinephrine 1:100,000/ Astra, Westbrough, MA) was applied, the full thickness trapezoidal flap was raised large enough to provide adequate view of the defect area. Subgingival debridement and root planning were performed with the use of area-specific curets (Gracey curets, Hu-Friedy), and granulation tissue was removed (Figure 2a). The blood supply of the defect areas was taken into account. At the test site, IBDs were filled with T-PRF and T-PRF membranes were adapted over the defects both buccally and lingually, in addition to OFD (Figure 2b). Then mucoperiosteal flaps were repositioned with sutured with 4/0 monoprolene sutures.
Study NCT05925816 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: Video uses BA techniques for approximately 5 minutes
Study NCT05925816 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video
Description: Video uses BA techniques for approximately 5 minutes
Study NCT05925816 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active game
Description: Game provides positive feedback in response to decisions made by participants
Study NCT05925816 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Neutral game
Description: Game without feedback
Study NCT05925816 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neutral game
Description: Game without feedback
Study NCT06116461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Participants receive three reduced doses of 240 mg every four weeks
Study NCT06284122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 50 mg/m2 Day 1 from C1 to C6